Gentech: The first equipment launch ceremony of the biopharmaceutical R&D and manufacturing base was officially held

On June 16th, the completion ceremony of Zhengfan Technology's biopharmaceutical R&D and manufacturing base and the launch ceremony of the first equipment were officially held in Minhang District, Shanghai. This marks a new breakthrough for Zhengfan Technology in the level of modular process equipment for large-scale production of high-end pharmaceutical projects.

Zhengfan Biological Pharmaceutical R&D and Manufacturing Base Project was officially established on February 1, 2021. The project will build a new pharmaceutical process system module manufacturing workshop of 1200 square meters. After the project is officially put into production, Zhengfan Technology will also provide a complete vaccine process system production base to meet the annual capacity demand of 100 sets of COVID-19 vaccine core process systems.

The project leader mentioned in the ceremony speech that currently, assisting vaccine production is an unshirkable responsibility of every enterprise, and it will also be an important opportunity to strive for more market share in the future. Relying on its own advantages and industrial capabilities, Zhengfan Technology will closely cooperate with more vaccine and biopharmaceutical companies, seize the opportunity of the new round of "united fight against the epidemic" industry development, provide manufacturing regional advantages for process system module manufacturing, inject new momentum into the annual production of the business unit, and even the development of the entire Zhengfan Technology.

At present, Zhengfan Biological Pharmaceutical R&D and Manufacturing Base is committed to product production, R&D and innovation with "mixing test platform, cell reaction platform and ultrafiltration purification process test platform" as the core, and these three test platforms have been successfully invested in the R&D and production of COVID-19 vaccines and other veterinary vaccines, such as Keqian Biological Veterinary Vaccine, Yuxi Watson mRNA COVID-19 Vaccine, Oskonconnexino Vaccine. In the future, Zhengfan Technology will focus on the research and production of high-level equipment such as biological fermentation and cell culture, and expand disposable products at this base to provide highly reliable domestic solutions for domestic high-end biopharmaceutical enterprises.

I believe that with the successive launch and production of subsequent equipment, Zhengfan Technology will enable more core process systems to blossom and bear fruit in vaccine and biopharmaceutical enterprises nationwide and even globally, achieving a virtuous cycle of collaborative development and mutual benefit.